Sarepta Therapeutics (SRPT) Invested Capital (2010 - 2026)

Sarepta Therapeutics has reported Invested Capital for 17 years, with the latest figure at $2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 105.06% year-over-year to $2.3 billion; the trailing twelve-month figure through Mar 2026 stood at $2.3 billion (up 105.06% YoY), and the FY2025 full-year result was $2.0 billion, down 26.09% from the prior year.
• Invested Capital for Q1 2026 stood at $2.3 billion, up from $2.0 billion in the prior quarter.
• The five-year high for Invested Capital was $2.7 billion in Q4 2024, with the low at $1.1 billion in Q1 2025.
• Average Invested Capital over 5 years is $1.9 billion, with a median of $2.0 billion recorded in 2022.
• Year-over-year, Invested Capital plunged 48.07% in 2025 and surged 105.06% in 2026.
• Tracing SRPT's Invested Capital over 5 years: stood at $1.9 billion in 2022, then climbed by 8.71% to $2.1 billion in 2023, then gained by 27.06% to $2.7 billion in 2024, then retreated by 26.09% to $2.0 billion in 2025, then climbed by 18.97% to $2.3 billion in 2026.
• The last three Invested Capital figures came in at $2.3 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.

Peer Comparison